Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12072-024-10676-4 | DOI Listing |
Int Neurourol J
December 2024
Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
Purpose: We aimed to assess the clinical efficacy and safety of combining silodosin and solifenacin for overactive bladder (OAB) in females.
Methods: A retrospective analysis of 586 females with OAB was conducted. Patients received either combination therapy (silodosin 8 mg + solifenacin 5 mg) or monotherapy (solifenacin 5 mg) for 12 weeks.
Low Urin Tract Symptoms
January 2025
Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Objectives: This study aimed to evaluate the clinical efficacy and safety of silodosin in female patients with lower urinary tract symptoms (LUTSs), addressing the limited evidence supporting alpha-blocker use in this population.
Methods: A 12-week, single-arm, prospective, open-label study was conducted from May 2021 to January 2023. Female patients aged over 18 with an International Prostate Symptom Score (IPSS) ≥ 8 were enrolled and treated with silodosin (8 mg once daily).
J Child Adolesc Psychopharmacol
January 2025
Consultant, Pittsford, NY, USA.
Approximately 20%-40% of individuals with Tourette syndrome (TS) have rage attacks (RAs), which are recurrent, explosive behavioral outbursts that can cause significant functional impairment. Despite the impact of RA in TS, there has been limited research on treatment, and most studies have focused on pharmacologic interventions. Nonpharmacologic interventions have the potential to improve symptoms with fewer side effects.
View Article and Find Full Text PDFClin Exp Emerg Med
December 2024
Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Surg Oncol
December 2024
HBP and Multi-Organ Transplant Program, Division of General Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
Introduction: Patients with advanced hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) are recommended to receive systemic therapy according to guidelines. Stereotactic body radiotherapy (SBRT) and surgery are increasingly used in this patient population. This study compares outcomes from these local treatments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!